Allergological and Occupational Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
Dermatitis. 2013 Jul-Aug;24(4):166-9. doi: 10.1097/DER.0b013e3182987773.
Chronic hand eczema (CHE) is a common disease that has a major impact on patients' health and on society.
The purpose of this observational, open-label study was to assess the efficacy of treatment with 30 mg/d of oral alitretinoin on the quality of life (QoL) in a group of patients affected by CHE.
This study included 15 patients, all suffering from severe CHE refractory to treatment with potent topical corticosteroids, who underwent treatment with 30 mg/d of alitretinoin for a period of 3 months. At the 1- and 3-month points, together with a clinical evaluation, the QoL of these patients were evaluated by the Dermatology Life Quality Index and visual analog scale (EQ5D-VAS).
The oral administration of alitretinoin led to a notable QoL improvement among the patients, as shown by the statistically significant improvement in the Dermatology Life Quality Index and in the EQ5D-VAS after 1 and 3 months of therapy.
本观察性、开放性研究旨在评估口服阿利特罗汀 30mg/d 治疗一组手部慢性湿疹（CHE）患者对生活质量（QoL）的疗效。
本研究纳入了 15 名患者，他们均患有严重的 CHE，对外用强效皮质类固醇治疗难治，接受了 30mg/d 的阿利特罗汀治疗，为期 3 个月。在第 1 个月和第 3 个月，除了临床评估外，还通过皮肤病生活质量指数（Dermatology Life Quality Index）和视觉模拟量表（EQ5D-VAS）评估这些患者的 QoL。
口服阿利特罗汀治疗显著改善了患者的 QoL，治疗 1 个月和 3 个月后，皮肤病生活质量指数和 EQ5D-VAS 均有统计学显著改善。
